Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy

Bas W G van Rhijn, Maximilian Burger, Yair Lotan, Eduardo Solsona, Christian G. Stief, Richard J. Sylvester, J. Alfred Witjes, Alexandre R. Zlotta

Research output: Contribution to journalArticle

392 Citations (Scopus)

Abstract

Context: This review focuses on the prediction of recurrence and progression in non-muscle invasive bladder cancer (NMIBC) and the treatments advocated for this disease. Objective: To review the current status of epidemiology, recurrence, and progression of NMIBC and the state-of-the art treatment for this disease. Evidence acquisition: A literature search in English was performed using PubMed and the guidelines of the European Association of Urology and the American Urological Association. Relevant papers on epidemiology, recurrence, progression, and management of NMIBC were selected. Special attention was given to fluorescent cystoscopy, the new World Health Organisation 2004 classification system for grade, and the role of substaging of T1 NMIBC. Evidence synthesis: In NMIBC, approximately 70% of patients present as pTa, 20% as pT1, and 10% with carcinoma in situ (CIS) lesions. Bladder cancer (BCa) is the fifth most frequent type of cancer in western society and the most expensive cancer per patient. Recurrence (in ≤80% of patients) is the main problem for pTa NMIBC patients, whereas progression (in ≤45% of patients) is the main threat in pT1 and CIS NMIBC. In a recent European Organisation for Research and Treatment of Cancer analysis, multiplicity, tumour size, and prior recurrence rate are the most important variables for recurrence. Tumour grade, stage, and CIS are the most important variables for progression. Treatment ranges from transurethral resection (TUR) followed by a single chemotherapy instillation in low-risk NMIBC to, sometimes, re-TUR and adjuvant intravesical therapy in intermediate- and high-risk patients to early cystectomy for treatment-refractory high-risk NMIBC. Conclusions: NMIBC is a heterogeneous disease with varying therapies, follow-up strategies, and oncologic outcomes for an individual patient.

Original languageEnglish (US)
Pages (from-to)430-442
Number of pages13
JournalEuropean Urology
Volume56
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Urinary Bladder Neoplasms
Disease Progression
Epidemiology
Recurrence
Carcinoma in Situ
Therapeutics
Neoplasms
Cystoscopy
Cystectomy
PubMed
Guidelines
Drug Therapy

Keywords

  • BCG
  • Bladder cancer
  • Cystectomy
  • Cystoscopy
  • Epidemiology
  • Grade
  • Progression
  • Recurrence
  • Stage
  • Treatment

ASJC Scopus subject areas

  • Urology

Cite this

Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer : From Epidemiology to Treatment Strategy. / van Rhijn, Bas W G; Burger, Maximilian; Lotan, Yair; Solsona, Eduardo; Stief, Christian G.; Sylvester, Richard J.; Witjes, J. Alfred; Zlotta, Alexandre R.

In: European Urology, Vol. 56, No. 3, 09.2009, p. 430-442.

Research output: Contribution to journalArticle

van Rhijn, BWG, Burger, M, Lotan, Y, Solsona, E, Stief, CG, Sylvester, RJ, Witjes, JA & Zlotta, AR 2009, 'Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy', European Urology, vol. 56, no. 3, pp. 430-442. https://doi.org/10.1016/j.eururo.2009.06.028
van Rhijn, Bas W G ; Burger, Maximilian ; Lotan, Yair ; Solsona, Eduardo ; Stief, Christian G. ; Sylvester, Richard J. ; Witjes, J. Alfred ; Zlotta, Alexandre R. / Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer : From Epidemiology to Treatment Strategy. In: European Urology. 2009 ; Vol. 56, No. 3. pp. 430-442.
@article{235b3cd632b84e91a2c99921955459a5,
title = "Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy",
abstract = "Context: This review focuses on the prediction of recurrence and progression in non-muscle invasive bladder cancer (NMIBC) and the treatments advocated for this disease. Objective: To review the current status of epidemiology, recurrence, and progression of NMIBC and the state-of-the art treatment for this disease. Evidence acquisition: A literature search in English was performed using PubMed and the guidelines of the European Association of Urology and the American Urological Association. Relevant papers on epidemiology, recurrence, progression, and management of NMIBC were selected. Special attention was given to fluorescent cystoscopy, the new World Health Organisation 2004 classification system for grade, and the role of substaging of T1 NMIBC. Evidence synthesis: In NMIBC, approximately 70{\%} of patients present as pTa, 20{\%} as pT1, and 10{\%} with carcinoma in situ (CIS) lesions. Bladder cancer (BCa) is the fifth most frequent type of cancer in western society and the most expensive cancer per patient. Recurrence (in ≤80{\%} of patients) is the main problem for pTa NMIBC patients, whereas progression (in ≤45{\%} of patients) is the main threat in pT1 and CIS NMIBC. In a recent European Organisation for Research and Treatment of Cancer analysis, multiplicity, tumour size, and prior recurrence rate are the most important variables for recurrence. Tumour grade, stage, and CIS are the most important variables for progression. Treatment ranges from transurethral resection (TUR) followed by a single chemotherapy instillation in low-risk NMIBC to, sometimes, re-TUR and adjuvant intravesical therapy in intermediate- and high-risk patients to early cystectomy for treatment-refractory high-risk NMIBC. Conclusions: NMIBC is a heterogeneous disease with varying therapies, follow-up strategies, and oncologic outcomes for an individual patient.",
keywords = "BCG, Bladder cancer, Cystectomy, Cystoscopy, Epidemiology, Grade, Progression, Recurrence, Stage, Treatment",
author = "{van Rhijn}, {Bas W G} and Maximilian Burger and Yair Lotan and Eduardo Solsona and Stief, {Christian G.} and Sylvester, {Richard J.} and Witjes, {J. Alfred} and Zlotta, {Alexandre R.}",
year = "2009",
month = "9",
doi = "10.1016/j.eururo.2009.06.028",
language = "English (US)",
volume = "56",
pages = "430--442",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer

T2 - From Epidemiology to Treatment Strategy

AU - van Rhijn, Bas W G

AU - Burger, Maximilian

AU - Lotan, Yair

AU - Solsona, Eduardo

AU - Stief, Christian G.

AU - Sylvester, Richard J.

AU - Witjes, J. Alfred

AU - Zlotta, Alexandre R.

PY - 2009/9

Y1 - 2009/9

N2 - Context: This review focuses on the prediction of recurrence and progression in non-muscle invasive bladder cancer (NMIBC) and the treatments advocated for this disease. Objective: To review the current status of epidemiology, recurrence, and progression of NMIBC and the state-of-the art treatment for this disease. Evidence acquisition: A literature search in English was performed using PubMed and the guidelines of the European Association of Urology and the American Urological Association. Relevant papers on epidemiology, recurrence, progression, and management of NMIBC were selected. Special attention was given to fluorescent cystoscopy, the new World Health Organisation 2004 classification system for grade, and the role of substaging of T1 NMIBC. Evidence synthesis: In NMIBC, approximately 70% of patients present as pTa, 20% as pT1, and 10% with carcinoma in situ (CIS) lesions. Bladder cancer (BCa) is the fifth most frequent type of cancer in western society and the most expensive cancer per patient. Recurrence (in ≤80% of patients) is the main problem for pTa NMIBC patients, whereas progression (in ≤45% of patients) is the main threat in pT1 and CIS NMIBC. In a recent European Organisation for Research and Treatment of Cancer analysis, multiplicity, tumour size, and prior recurrence rate are the most important variables for recurrence. Tumour grade, stage, and CIS are the most important variables for progression. Treatment ranges from transurethral resection (TUR) followed by a single chemotherapy instillation in low-risk NMIBC to, sometimes, re-TUR and adjuvant intravesical therapy in intermediate- and high-risk patients to early cystectomy for treatment-refractory high-risk NMIBC. Conclusions: NMIBC is a heterogeneous disease with varying therapies, follow-up strategies, and oncologic outcomes for an individual patient.

AB - Context: This review focuses on the prediction of recurrence and progression in non-muscle invasive bladder cancer (NMIBC) and the treatments advocated for this disease. Objective: To review the current status of epidemiology, recurrence, and progression of NMIBC and the state-of-the art treatment for this disease. Evidence acquisition: A literature search in English was performed using PubMed and the guidelines of the European Association of Urology and the American Urological Association. Relevant papers on epidemiology, recurrence, progression, and management of NMIBC were selected. Special attention was given to fluorescent cystoscopy, the new World Health Organisation 2004 classification system for grade, and the role of substaging of T1 NMIBC. Evidence synthesis: In NMIBC, approximately 70% of patients present as pTa, 20% as pT1, and 10% with carcinoma in situ (CIS) lesions. Bladder cancer (BCa) is the fifth most frequent type of cancer in western society and the most expensive cancer per patient. Recurrence (in ≤80% of patients) is the main problem for pTa NMIBC patients, whereas progression (in ≤45% of patients) is the main threat in pT1 and CIS NMIBC. In a recent European Organisation for Research and Treatment of Cancer analysis, multiplicity, tumour size, and prior recurrence rate are the most important variables for recurrence. Tumour grade, stage, and CIS are the most important variables for progression. Treatment ranges from transurethral resection (TUR) followed by a single chemotherapy instillation in low-risk NMIBC to, sometimes, re-TUR and adjuvant intravesical therapy in intermediate- and high-risk patients to early cystectomy for treatment-refractory high-risk NMIBC. Conclusions: NMIBC is a heterogeneous disease with varying therapies, follow-up strategies, and oncologic outcomes for an individual patient.

KW - BCG

KW - Bladder cancer

KW - Cystectomy

KW - Cystoscopy

KW - Epidemiology

KW - Grade

KW - Progression

KW - Recurrence

KW - Stage

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=67651092245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651092245&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2009.06.028

DO - 10.1016/j.eururo.2009.06.028

M3 - Article

C2 - 19576682

AN - SCOPUS:67651092245

VL - 56

SP - 430

EP - 442

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 3

ER -